p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma.
about
MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.Neoplasia: Where We Have Been and Where We Are GoingLosses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesisNeoplasia: the second decade.MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.Sensitivity of global translation to mTOR inhibition in REN cells depends on the equilibrium between eIF4E and 4E-BP1.Zoledronic acid produces combinatory anti-tumor effects with cisplatin on mesothelioma by increasing p53 expression levels.NF2 blocks Snail-mediated p53 suppression in mesothelioma.Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.Expression of p14ARF, MDM2, and MDM4 in human retinoblastoma.Expression of cancer-associated molecules in malignant mesotheliomaNew diagnostic and molecular characteristics of malignant mesothelioma.Gene therapy for malignant mesothelioma: current prospects and challenges.Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53.Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.Mechanisms of cisplatin-induced cell death in malignant mesothelioma cells: role of inhibitor of apoptosis proteins (IAPs) and caspasesSynergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.Neoplasia: An Anniversary of Progress.Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.Clinical and biologic prognostic factors in malignant pleural mesothelioma.Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed.
P2860
Q27853125-407E3788-07C7-4A84-AF6E-E3A8DF4DB1C2Q28395095-2829EB93-CCF7-407F-92A5-59103684A9B3Q28740925-2CD16D63-378A-4ACE-919A-D27328736BFFQ30484000-18BFE769-C9D2-47BA-A3BE-5D6B62578915Q31019143-2B30AB4F-9EE9-467B-A4C5-899412471ADBQ34117251-F92A2866-682E-4DD2-BFC7-7B0D78457B22Q34653709-3BF6FBC6-AF27-4245-9E99-9F248271CB05Q35832918-A96010B1-BBB4-499A-983E-6EAC425EF6DCQ36259724-19F9D5CE-DFE3-4362-8436-2710D007D5CEQ37004455-E092DF03-0B72-4F73-B15D-F2E93408EFCFQ37281015-729CCB7D-3B14-4EF6-99C5-312BFF747134Q37360580-E252C1CB-A6C0-4DF7-98CE-16D89D00CC5CQ38079969-3BDF3BB6-2D2E-4D01-9420-CD701C5E2F1CQ38741344-0227A2BD-1CE0-401F-A142-AA29B4F09743Q39042562-3B72C7AD-C729-415C-B2CC-CB95062931DEQ39228453-A1CE8FD9-57F8-4C02-B274-43515AC5CB45Q41279899-8DE6C775-B51B-40A6-B584-D89D273E46CEQ46932476-362203EC-94C9-4005-9367-B7C8F16D2041Q49996923-CD9B3BBA-748D-4EC9-A868-A20F2DC1AB61Q50050310-B3F66A29-DDB5-4170-8030-CE97A11454C8Q53193985-9D83F6D8-3190-4167-AFD7-45E9D5B959B5
P2860
p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
p53-induced apoptosis occurs i ...... alignant pleural mesothelioma.
@en
type
label
p53-induced apoptosis occurs i ...... alignant pleural mesothelioma.
@en
prefLabel
p53-induced apoptosis occurs i ...... alignant pleural mesothelioma.
@en
P2093
P2860
P356
P1433
P1476
p53-induced apoptosis occurs i ...... alignant pleural mesothelioma.
@en
P2093
Ana Paula Simões-Wüst
Brigitte Sigrist
Larisa L Belyanskaya
Rolf Stahel
Sally Hopkins-Donaldson
Stefanie Kurtz
Uwe Zangemeister-Wittke
P2860
P304
P356
10.1593/NEO.06148
P577
2006-07-01T00:00:00Z